CLINICAL_TRIALS ClinicalTrials.gov record update

Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00914732
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:50.237087+00:00
Published At: 2021-01-12T00:00:00+00:00
Record Updated At: 2021-02-03
Results Posted At: 2021-01-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Smallpox"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-02-03"
protocolSection.identificationModule.nctId: "NCT00914732"
protocolSection.identificationModule.officialTitle: "Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE\u00ae (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE\u00ae (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE\u00ae (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Na\u00efve Individuals"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2021-01-12"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.